Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat

Clinical and Experimental Hypertension

Volumn 28, Issue 5, 2006, Pages 499-509

  Mondo, Charles Kiiza ^a   Yang, Wan Song ^a   Su, Ji Zhou ^a   Huang, Ti Gang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Blood pressure; Dexamethasone; Rat

Indexed keywords

ANTIOXIDANT; ATORVASTATIN; DEXAMETHASONE; NITRATE; NITRITE; SODIUM CHLORIDE; SUPEROXIDE; TAP WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; ORGAN WEIGHT; PREVENTION STUDY; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; THYMUS; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY WEIGHT; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GLUCOCORTICOIDS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; NITRATES; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; ORGAN SIZE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDES; THYMUS GLAND;

EID: 33745861349     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600798713     Document Type: Article

References (32)

1. Li M, Fraser T, Wang J, Whitworth JA. Dexamethasone-induced hypertension in the rat: effects of L-arginine. Clin Exp Pharmacol Physiol 1997; 24:730-732.
2. Zhang Y, Croft KD, Mori TA, Schyvens CG, McKenzie KU, Whitworth JA. The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2004; 17:260-265.
3. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343:425-430.
4. Levine G, Keaney J, Vital J. Cholesterol reduction in cardiovascular disease. N Eng J Med 1995; 332:512-521.
5. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-2719.
6. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-305.
7. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 2002; 40:611-617.
8. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37:1450-1457.
9. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39:135-141.
10. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001; 37:781-786.
11. 2a. Hypertension 1999; 33:424-428.
12. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44:186-190.
13. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995; 41:892-896.
14. Mantero F, Takeda R, Scoggins BA, Biglieri EG, Funder JW, Eds. Adrenocortical steroid hypertension: a historical perspective. In: The adrenal and hypertension: from cloning to clinic. Serono symposia. New York: Raven Press, 1989, 177-190.
15. Turner SW, Wen C, Li M, Fraser TB, Whitworth JA. Adrenocorticotrophin dose-response relationships in the rat: haemodynamic, metabolic and hormonal effects. J Hypertens 1998; 16:593-600.
16. Wen C, Li M, Fraser T, Wang J, Turner SW, Whitworth JA. L-arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat. Blood Press 2000; 9:298-304.
17. Turner SW, Wen C, Li M, Whitworth JA. L-arginine prevents corticotropin-induced increases in blood pressure in the rat. Hypertension 1996; 27:184-189.
18. Goulding NJ, Flower RJ, Eds. Glucocorticoid biology - a historical perspective. In: Glucocorticoids (milestones in drug therapy). 1st ed. Basal: Birkhäuser Verlag, 2001, 18.
19. Whitworth JA, Gordon D, McLachlan-Troup N, Scoggins BA, Moulds RW. Dexamethasone suppression in essential hypertension: effects on cortisol and blood pressure. Clin Exp Hypertens 1989; 11:323-335.
20. Walker BR, Best R, Shackleton CH, Padfield PL, Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996; 27:190-196.
21. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
22. Gresser U, Gathof BS. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled end-point studies. Eur J Med Res 2004; 9:1-17.
23. Tayek J. Atorvastatin reduced coronary and stroke events in patients with hypertension and without dyslipidemia. ACP J Club 2004; 140:A16.
24. Croom KF, Plosker GL. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005; 65:137-152.
25. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64 Suppl 2:43-60.
26. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
27. Zhang M, Liu L, Cheng L, Zhang P. [Expression of plasma ROS, SOD, and GSH-PX in patients with nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2003; 17:650-651.
28. Zhou SG, Xu LP, Liao DF, Lei XY, Yan FX, Zhu BY. Cyclosporin A inhibits the adhesion of neutrophil with ECV-304 induced by hypoxia/reoxygenation via ROS-Cyclophilin A-ERK1/2 pathway. Sheng Li Xue Bao 2004; 56:313-320.
29. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, et al. Long-term inhibition of rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93:767-775.
30. Menschikowski M, Hagelgans A, Heyne B, Hempel U, Neumeister V, Goez P, et al. Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim Biophys Acta 2005; 1733:157-171.
31. Senokuchi T, Matsumura T, Sakai M, Yano M, Taguchi T, Matsuo T, et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem 2005; 280:6627-6633.
32. Tramontano AF, O'Leary J, Black AD, Muniyappa R, Cutaia MV, El-Sherif N. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the rho-kinase pathway. Biochem Biophys Res Commun 2004; 320:34-38.